Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Does the presence of a BRCA 1/2 mutation affect your recommendation for post-mastectomy RT in patients with pT1-2, N0 disease?
Answer from: Radiation Oncologist at Community Practice
It doesn’t influence RT decision.
Sign in or Register to read more
11230
Related Questions
In cT4aN0 triple negative breast cancer would you still recommend PMRT if pCR, ypT0N0(sn), after neoadj chemo is achieved?
Have the breast surgeons at your institution adopted the SOUND trial into their clinical practice?
Is keratosis follicularis (Darier disease) a contraindication to receipt of PMRT?
Do you recommend self-breast exams to your patients with history of breast cancer in addition to imaging surveillance?
Is there any contraindication for a patient receiving omalizumab for treatment of her lung aspergillosis to receive adjuvant breast radiotherapy?
What is your preferred sequencing of adjuvant chemotherapy and PMRT for node + breast cancer?
What is your preferred method of surveillance after mastectomy?
What is your approach to a tumor bed boost in early stage breast cancer patients with micrometastasis?
Do you consider chest wall constraints when treating with 5-fraction APBI?
How would you treat a patient with HER2 positive CNS only progression on fam-trastuzumab which had previously progressed on tucatinib/capecitabine/trastuzumab, and has failed both SRS and WBRT?